Form 4: Sight Sciences Director and 10% Owner Staffan Encrantz Boosts Stake with Significant Stock Purchases and RSU Grant

Staffan Encrantz, a Director and 10% owner of Sight Sciences, Inc. (SGHT), has increased his direct beneficial ownership through multiple stock purchases totaling 90,525 shares and a grant of 30,952 restricted stock units (RSUs) in early June 2025.

Summary

• Staffan Encrantz, a Director and 10% owner of Sight Sciences, Inc. (SGHT), reported multiple transactions increasing his beneficial ownership.
• On June 4, 2025, Mr. Encrantz purchased 21,674 shares of Common Stock at a weighted average price of $4.172 per share, with prices ranging from $4.067 to $4.23.
• On June 5, 2025, he purchased an additional 40,951 shares at a weighted average price of $4.244 per share, with prices ranging from $4.19 to $4.295.
• Also on June 5, 2025, Mr. Encrantz received a grant of 30,952 restricted stock units (RSUs) under the Issuer's Non-Employee Director Compensation Program, valued at approximately $130,000 based on the closing price on the grant date.
• On June 6, 2025, he purchased 27,900 shares at a weighted average price of $4.22 per share, with prices ranging from $4.20 to $4.245.
• Following these transactions, Mr. Encrantz's direct beneficial ownership stands at 1,377,964 shares, which includes 1,347,012 shares of Common Stock and 30,952 restricted stock units subject to vesting.
• Additionally, Mr. Encrantz indirectly holds 632,456 shares through the 1997 Staffan Encrantz and Margareta Encrantz Revocable Trust, and 5,086,920 shares through Allegro Investment Fund, L.P., though he disclaims pecuniary interest and beneficial ownership for these indirect holdings for Section 16 purposes.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to significant insider buying by a director and 10% owner, indicating strong confidence in the company's value and future performance. The RSU grant further aligns management interests with shareholders.

Positives

• A Director and 10% owner, Staffan Encrantz, made significant direct purchases of 90,525 shares of Sight Sciences common stock, indicating strong insider confidence in the company's future prospects.
• The purchases were made at prices ranging from $4.067 to $4.295, demonstrating a willingness to invest personal capital at current market valuations.
• The grant of 30,952 restricted stock units (RSUs) to Mr. Encrantz, valued at approximately $130,000, aligns his interests with long-term shareholder value through a vesting schedule tied to continued service.

Future Outlook

The document does not provide a future outlook or guidance; it is a report of insider transactions.

Management Comments

• The grant of restricted stock units (RSUs) was made to the Reporting Person under the Issuer's Non-Employee Director Compensation Program, indicating a structured approach to director remuneration and alignment of interests.

Industry Context

Insider buying, particularly by a director and significant owner, often signals strong internal confidence in the company's valuation and future prospects, potentially indicating that the insider believes the stock is undervalued or expects positive developments. This can be a positive indicator for investors in the medical device or ophthalmology sector.

Corporate Governance

Related Party Transactions

• Staffan Encrantz indirectly holds 632,456 shares through the 1997 Staffan Encrantz and Margareta Encrantz Revocable Trust, where he is a trustee, though he disclaims beneficial ownership except for pecuniary interest.
• Staffan Encrantz indirectly holds 5,086,920 shares through Allegro Investment Fund, L.P., where he is the President and sole director of the investment manager, Allegro Investment Inc. He disclaims beneficial ownership due to no pecuniary interest, reporting these shares voluntarily for informational purposes.

Stakeholder Impact

• Shareholders may view the significant insider buying as a positive signal, potentially increasing investor confidence and demand for the stock.
• The RSU grant aligns the interests of the director with long-term shareholder value, benefiting existing shareholders.

Next Steps

• The 30,952 restricted stock units (RSUs) granted on June 5, 2025, are scheduled to vest on the earlier of June 5, 2026, or the date of the Issuer's 2026 annual meeting of stockholders, subject to continued service.

Key Dates

Recommendation

Keywords

Sight Sciences, SGHT, Form 4, Insider Trading, Stock Purchase, Restricted Stock Units, RSU, Beneficial Ownership, Staffan Encrantz, Director, 10% Owner